Cytoreductive Nephrectomy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2011-11-29

AUTHORS

Scott E. Delacroix , Brian F. Chapin , Christopher G. Wood

ABSTRACT

Cytoreductive nephrectomy (CN) continues to be an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitnib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, discuss the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC. More... »

PAGES

109-121

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_7

DOI

http://dx.doi.org/10.1007/978-3-642-21858-3_7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004285525


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delacroix", 
        "givenName": "Scott E.", 
        "id": "sg:person.01274241527.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274241527.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chapin", 
        "givenName": "Brian F.", 
        "id": "sg:person.01202352702.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202352702.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-11-29", 
    "datePublishedReg": "2011-11-29", 
    "description": "Cytoreductive nephrectomy (CN) continues to be an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitnib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, discuss the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.", 
    "editor": [
      {
        "familyName": "Lara,", 
        "givenName": "Primo N.", 
        "type": "Person"
      }, 
      {
        "familyName": "Jonasch", 
        "givenName": "Eric", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-21858-3_7", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-21857-6", 
        "978-3-642-21858-3"
      ], 
      "name": "Kidney Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "cytoreductive nephrectomy", 
      "optimal patient selection", 
      "overall survival", 
      "metastatic RCC", 
      "patient selection", 
      "timing of CN", 
      "multidisciplinary treatment paradigm", 
      "large phase III", 
      "treatment of patients", 
      "renal cell carcinoma", 
      "tyrosine kinase inhibitors", 
      "cytokine therapy", 
      "cell carcinoma", 
      "primary tumor", 
      "treatment paradigm", 
      "FDA approval", 
      "patients", 
      "surgery", 
      "kinase inhibitors", 
      "phase III", 
      "therapy paradigm", 
      "nephrectomy", 
      "therapy", 
      "trials", 
      "RCC", 
      "treatment", 
      "risk", 
      "carcinoma", 
      "tumors", 
      "cancer", 
      "physicians", 
      "survival", 
      "inhibitors", 
      "approval", 
      "future methods", 
      "controversy", 
      "integral part", 
      "role", 
      "timing", 
      "data", 
      "optimal integration", 
      "removal", 
      "paradigm", 
      "selection", 
      "malate", 
      "results", 
      "part", 
      "method", 
      "chapter", 
      "integration", 
      "historical evolution", 
      "evolution"
    ], 
    "name": "Cytoreductive Nephrectomy", 
    "pagination": "109-121", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004285525"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-21858-3_7"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-21858-3_7", 
      "https://app.dimensions.ai/details/publication/pub.1004285525"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_393.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-21858-3_7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_7'


 

This table displays all metadata directly associated to this object as RDF triples.

131 TRIPLES      22 PREDICATES      76 URIs      69 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-21858-3_7 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nba54635dedb8475ea274948568634a54
4 schema:datePublished 2011-11-29
5 schema:datePublishedReg 2011-11-29
6 schema:description Cytoreductive nephrectomy (CN) continues to be an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitnib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, discuss the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.
7 schema:editor N421239ac8c984e77835ff50678cb4743
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N32abdfde3aa847cc89a0395907bb02d1
11 schema:keywords FDA approval
12 RCC
13 approval
14 cancer
15 carcinoma
16 cell carcinoma
17 chapter
18 controversy
19 cytokine therapy
20 cytoreductive nephrectomy
21 data
22 evolution
23 future methods
24 historical evolution
25 inhibitors
26 integral part
27 integration
28 kinase inhibitors
29 large phase III
30 malate
31 metastatic RCC
32 metastatic renal cell carcinoma
33 method
34 multidisciplinary treatment paradigm
35 nephrectomy
36 optimal integration
37 optimal patient selection
38 overall survival
39 paradigm
40 part
41 patient selection
42 patients
43 phase III
44 physicians
45 primary tumor
46 removal
47 renal cell carcinoma
48 results
49 risk
50 role
51 selection
52 surgery
53 survival
54 therapy
55 therapy paradigm
56 timing
57 timing of CN
58 treatment
59 treatment of patients
60 treatment paradigm
61 trials
62 tumors
63 tyrosine kinase inhibitors
64 schema:name Cytoreductive Nephrectomy
65 schema:pagination 109-121
66 schema:productId N03a356261a1b4f87b9d27267cd5d105e
67 N893aab3dfde34feb876379e45b7c9b36
68 schema:publisher N0c7e9921072a4bde898add6942ddaa40
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004285525
70 https://doi.org/10.1007/978-3-642-21858-3_7
71 schema:sdDatePublished 2022-09-02T16:15
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher N8abf47124cbf43ebbdfefebb376d732c
74 schema:url https://doi.org/10.1007/978-3-642-21858-3_7
75 sgo:license sg:explorer/license/
76 sgo:sdDataset chapters
77 rdf:type schema:Chapter
78 N03a356261a1b4f87b9d27267cd5d105e schema:name doi
79 schema:value 10.1007/978-3-642-21858-3_7
80 rdf:type schema:PropertyValue
81 N0c7e9921072a4bde898add6942ddaa40 schema:name Springer Nature
82 rdf:type schema:Organisation
83 N21ad30bce3944bc8802dfc1029e1d014 rdf:first sg:person.01202352702.54
84 rdf:rest N595d53efa42b4d97ae85f0c8738bc4d8
85 N32abdfde3aa847cc89a0395907bb02d1 schema:isbn 978-3-642-21857-6
86 978-3-642-21858-3
87 schema:name Kidney Cancer
88 rdf:type schema:Book
89 N421239ac8c984e77835ff50678cb4743 rdf:first Nbbffd80824e74adcb1655f74eb67260b
90 rdf:rest N4a707b9d61b74125a4dfb717d43379d0
91 N4a707b9d61b74125a4dfb717d43379d0 rdf:first Nf34b920cc2264b45bca1d1931441a2ab
92 rdf:rest rdf:nil
93 N595d53efa42b4d97ae85f0c8738bc4d8 rdf:first sg:person.01040121722.56
94 rdf:rest rdf:nil
95 N893aab3dfde34feb876379e45b7c9b36 schema:name dimensions_id
96 schema:value pub.1004285525
97 rdf:type schema:PropertyValue
98 N8abf47124cbf43ebbdfefebb376d732c schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 Nba54635dedb8475ea274948568634a54 rdf:first sg:person.01274241527.45
101 rdf:rest N21ad30bce3944bc8802dfc1029e1d014
102 Nbbffd80824e74adcb1655f74eb67260b schema:familyName Lara,
103 schema:givenName Primo N.
104 rdf:type schema:Person
105 Nf34b920cc2264b45bca1d1931441a2ab schema:familyName Jonasch
106 schema:givenName Eric
107 rdf:type schema:Person
108 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
109 schema:name Medical and Health Sciences
110 rdf:type schema:DefinedTerm
111 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
112 schema:name Oncology and Carcinogenesis
113 rdf:type schema:DefinedTerm
114 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
115 schema:familyName Wood
116 schema:givenName Christopher G.
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
118 rdf:type schema:Person
119 sg:person.01202352702.54 schema:affiliation grid-institutes:grid.240145.6
120 schema:familyName Chapin
121 schema:givenName Brian F.
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202352702.54
123 rdf:type schema:Person
124 sg:person.01274241527.45 schema:affiliation grid-institutes:grid.240145.6
125 schema:familyName Delacroix
126 schema:givenName Scott E.
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274241527.45
128 rdf:type schema:Person
129 grid-institutes:grid.240145.6 schema:alternateName Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
130 schema:name Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
131 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...